Disclosures for "A Retrospective Analysis of Factors Contributing to Delayed or Missed Treatment With Ocrelizumab in Patients With Multiple Sclerosis"
-
Dr. Sharba has nothing to disclose.
-
Preeta Gupta, MD has nothing to disclose.
-
Dr. Smith has received personal compensation for serving as an employee of Biohaven Pharmaceuticals. Dr. Smith has stock in Biohaven Pharmaceuticals.
-
Dr. Braley has received personal compensation in the range of $500-$4,999 for serving as a Consultant for Bluestar BioAdvisors. The institution of Dr. Braley has received research support from NIH. The institution of Dr. Braley has received research support from PCORI. The institution of Dr. Braley has received research support from National Multiple Sclerosis Society.